New York, USA – August 3, 2022 – Recently, immune checkpoint inhibitors have emerged as a promising class of immunotherapy for cancer management. So far, several immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have entered the market, and over 300 immune checkpoint inhibitors are in clinical trials, with a potential global market estimated at $30 billion approximately.
Based on a thorough understanding of signaling pathways and immune checkpoint molecules, Creative Biolabs has developed a comprehensive platform to afford immune checkpoint-associated antibodies, proteins, peptides, assays, small molecular drugs, etc.
Immune checkpoint-related services at Creative Biolabs:
• Immune checkpoint protein development
• Immune checkpoint antibody development
• Immune checkpoint targeted peptide development
• Immune checkpoint targeted small molecule drug development
• Biomarker development for immune checkpoint inhibitor
• Immune checkpoint assay
• Preclinical research on immune checkpoint drugs
Among these, with superior technical pipelines, immune checkpoint antibody development is a highlight service at Creative Biolabs. The service portfolio includes:
• Polyclonal antibody discovery and development
• Monoclonal antibody discovery and development
• Antibody fragment discovery and development
• Antibody characterization
• Antibody engineering and optimization
• Antibody production and manufacture
In addition, small molecules for immune checkpoint are also a compelling strategy as small molecule drugs are characterized by good spatial dispersion, drug properties, and pharmacokinetic properties. Current studies have revealed that a number of new checkpoint molecules have been verified for drug development and present anti-tumor activity in pre-clinical studies, such as 4-1BB, GITR, BTLA, B7-H4, TGF-ß, CD48, and BTNL2.
GITR and 4-1BB are costimulatory TNFR family members expressed on regulatory and effector T cells as well as the immune system of other cells.
4-1BB plays a critical role in sustaining effective T cell immune responses and generating immunological memory. In recent years, great progress has been made in elucidating the expression, function, and therapeutic potential of 4-1BB. GITR, also known as TNFRS18 or CD257, is an attractive target for immunotherapy, owing to its capacity to promote effector T cell functions and hamper regulatory T cell suppression. Creative Biolabs offers a wide range of services for drug development projects of diverse immune checkpoints like 4-1BB and GITR.
More information about immune checkpoint services can be found at https://immune-checkpoint.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs provides a full range of immune checkpoint antibody development services, immune checkpoint small molecule drug development services, and immune checkpoint assays. A series of high-quality immune checkpoint products are also available to support immune checkpoint research and drug discovery projects.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://immune-checkpoint.creative-biolabs.com
